Much to report and I apologize for the delay in updating. On a personal note, in spite of Covid 19 pandemic, I have never been busier in my work life than now. At the age of (almost) 63, I am starting new businesses in Europe and the US utilizing phone, email and Zoom/Facetime. I’m flunking retirement and loving every minute of it.
Project to chronicle success cases and more:
As noted previously, the Oklahoma Medical Research Foundation is in the process of auditing and building a data base of key success cases. But it gets more exciting.
A leading oncologist/scientist at Stanford reached out to OMRF to join the effort as they believe there is certainly something here. Why? They have seen first hand success with the protocol. They are now engaged looking at both successes and failures in concert with OMRF
Dr. Vikus Sukhatme, formerly Chief Medical Officer and Dean of Harvard Medical School and currently Chief Medical Officer and Dean of Emory Medical School, along with his wife Vidula, reached out to me due to my success story. Why? Dr. Sukhatme and his wife are firm believers in previously FDA approved drugs being repurposed for cancer. They have identified over 200 existing drugs that are being screened in various cocktails for such purpose. And along the way, they uncovered my story and reached out to join the effort. And now all of the work on this is being coordinated with and between Stanford, Emory and OMRF.
I can’t tell you how proud I am, as for the last 3 years, it has been me (a non MD, non PhD) hoping that people with credibility would listen.
We have their ears people and it is exciting to see where this takes us.
As you know, even auditing success cases is, in the eyes of mainstream medicine, only anecdotal evidence. Up until now it has been primarily my word against anyone out there challenging me (and there have been MANY unscrupulous attempts on my integrity).
Now, I can see a pathway to a real clinical trial that will be the non-anecdotal evidence that is necessary to change the most skeptical in the scientific community.
My Meeting yesterday (July 21, 2020) with MD Anderson Oncologist
So my last PET was Monday the 20th, 2020 (because of my extended remission I have gone to 6 months interval from the previous 3 months). And now for the 40th month, I am NED. I am not sure how many people realize what that really means coming from wide metastasis small cell lung cancer, where the life expectance is < 12 months and the long term survivability is literally 0%. But the response to 2 of my questions yesterday are VERY illuminating, particularly for skeptics about my protocol.
My former oncologist at MD Anderson moved to a different “cancer type” within MD Anderson. My new oncologist started the meeting by telling me “The reason I was assigned to you is simple….I am the lead within MDA on small cell lung cancer…and I have enormous passion for it”.
I asked him two questions and I think the answers are important for anyone reading this:
Q1: Now that I am 40 months in remission, how long do I need to go before I’m considered out of the woods?
A1: Nobody can answer that question for a very important reason. In the history of wide metastasis SCLC, there are only a handful of people that have made it as far as you, so opining on how long before you are out of the woods would be impossible. There is no data like yours.
Note on Second Question: As some of you might have noticed, I have had numerous people blatantly call my story BS for one simple reason…..I took the protocol concurrently with and parallel to an immunotherapy (Keytruda) clinical trial, and their reasoning was that there was no way I could ascertain whether it was my protocol or the Keytruda that did the trick. Hard to argue with them other than the fact that I have done a mountain of research and KNOW in my heart that, while Keytruda has been fairly successful with other cancer types (notably Non Small Cell Lung), it has been a well kept secret that it is not as successful with SCLC.
So Q2: What has been the true success of Keytruda with SCLC?
A2: It helps about 15% of the patients, but by help that doesn’t mean NED remission. Those 15% are seeing an extension of life, but not total remission.
So you be the judge, is my unheard of 40 months of remission due to Keytruda only? I don’t think so.
BUT…..I believe that future knowledge will say that immunotherapy and the protocol might be a “magic bullet” for many types of cancer.
And now you know why I give daily recommendations as follows:
Due to the low downside risk of the protocol, I recommend taking it concurrently with and parallel to any and all traditional medical protocols. There might just be complimentary co-effect that is still unknown.
Disgustingly, I have actually had multiple oncologists make the following statement to me and/or followers:
“I don’t want my patients to take the protocol because if it works we won’t know which one caused the success”
Are you kidding me? My answer immediately shuts them up: “If someone achieves success, why do you care which one, or a combination thereof, worked? Do you think your successful patient gives a shit?”
And finally, please tell people to re-read the blog for the very important updates on protocol items and dosages embedded throughout.